中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2014, Vol. 49 Issue (9) :786-789    DOI: 10.11669/cpj.2014.09.021
֪ʶ���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
�ŵͪ�࿹��ҩ��PK/PD�о���չ
���1a,����1b,�ŵ���2,���1a*
1.�й������ž���ҽԺ,a. ҩ���ٴ��о�����; b.ҩƷ��������,���� 100853; 2.����ѧԺҩѧ�뻯ѧѧԺ,���� ���� 671000
WANG Jin1a, BAI Yan1b,ZHANG Dan-dan2, WANG Rui1a*
1.a.Center of Medicine Clinical Research; b.Department of Pharmaceutical Care, Chinese PLA General Hospital, Beijing 100853, China; 2.School of Pharmacy and Chemistry, Dali University,Dali 671000, China

Download: PDF (905KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �����������Ƕ�ȫ���˽�Ŀǰ����������ŵͪ�࿹��ҩ��PK/PD�о��������ؽ�չ,ּ��Ϊ����о��ṩ�ο��ͽ�������� ͨ������Pubmed��Embase��SCIӢ�����ݿ⼰CNKI��ά�ա�SinoMed�������ݿ����ŵͪ�࿹��ҩ��PK/PD�������,������о��ȵ����ϵͳ��������� ���귢���������׵��о�������Ҫ�������ŵͪ�࿹��ҩ��PK/PD���۷�չ���ص㼰���ࡢ�������о����ٴ����顢��̬ģ�ͼ�ָ���ٴ�������ҩ�ȷ��档���� �ŵͪ�࿹��ҩ����һ���ٴ��㷺ʹ�õĹ��ס���Ч���Ͷ�����Ⱦ����ҩ����ڵ�����PK��PD�о�������ȫ�����ۿ���ҩ��-����-�²������߼�Ĺ�ϵ,ʹ��PK/PD���о��ѳ�Ϊ�ִ�ҩ������ѧ���ȵ㡣���߲��Ĺ�������ر�����������,���ֽ�����ŵͪ�࿹��ҩ��PK/PD�о������ܵ�ȫ��Χ�Ĺ㷺��ע,�о����ݸ������롣
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
���a
����b
�ŵ���
���a*
�ؼ����� �ŵͪ   ����ҩ��   PK/PD     
Abstract�� OBJECTIVE To review the recent advance on the research progression of quinolones from PK/PD over the past years. METHODS Literature search was conducted of Pubmed, Embase, CNKI, SinoMed and cqvip. Using ��quinolones�� and ��PK/PD or pharmacokinetics/pharmacodynamics�� as the keyword. RESULTS Now we review the research progression of quinolones from PK/PD theory, categorization and character of PK/PD, empirical study in vivo and in vitro and clinic study through refering to cognate report internal and abroad. CONCLUSION Owing to their broad-spectrum, high potency and low toxicity, quinolones have been widely used in clinic. Neither PK nor PD can value the relationships of antibacterials-body-pathogenic bacteria, so the research of PK/PD has been hot spot of modern pharmacotherapeutics.Many researchers pay more attention to quinolones from PK/PD and the research will be studied deeper.
Keywords�� quinolone,   antibacterial,   PK/PD     
�ո�����: 2013-05-31;
��������:ʮ��������ش�Ƽ�ר��(2012ZX09303004-002)
ͨѶ���� ���,Ů,����,��ʿ����ʦ �о�����:�ٴ�����Ⱦҩ��Tel:(010)66939709 E-mail:wangrui301@vip.sina.com   
���߼��: ���,Ů,������ҩʦ �о�����:ҩ���ٴ��������
���ñ���:   
���a, ����b, �ŵ����� .�ŵͪ�࿹��ҩ��PK/PD�о���չ[J]  �й�ҩѧ��־, 2014,V49(9): 786-789
WANG Jin-a, BAI Yan-b, ZHANG Dan-Dan- etc .The Research Progression of Quinolone Antibacterials in Pharmacokinetic-Pharmacodynamic[J]  Chinese Pharmaceutical Journal, 2014,V49(9): 786-789
��
[1] PICKERILL K E, PALADINO J A, SCHENTAG J J. Comparison of fluoroquinolones based on pharmakinetic and pharmocodynamic parameters. Pharmatherapy, 2000,20(4) :417-428.[2] MCDONALD M, BLONDEAU J M. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg, 2010, 36:1588-1598.[3] TONG M Q. PK/PD Theory of antibiotic and its application in study on pharmacodynamics of new antibiotic. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־), 2008,24(5):475-480.[4] ZHANG Q, CHENG Y J, GUO S Y, et al. Study of pharmacokinetics/pharmacodynamics of levofloxacin. Chin Med J(�л�ҽѧ��־),2005,85(27):1925-1932.[5] LI G Q. The pharmacodynamic study of a new fluoroquinolone antibiotic, chinfloxacin . Beijing: Graduate School of Peking Union Medical College,2011,1:117.[6] STEPNIEWSKA K, WHITE N J.Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother, 2008, 52:1589-1596.[7] DAI Z Y. Clinical Pharmacology of Antimicrobial(�ٴ�����ҩ��ѧ). Second Edition.Beijing: People's Medical Publishing House,1985:16-21.[8] CUI J C, LIU Y N, WANG R, et al. Correlation of levofloxacin pharmacokinetic/pharmacodynamic parameters with selection of staphylococcus aureus resistance. Chin J Clin Pharmacol Therapeutics(�й��ٴ�ҩ��ѧ������ѧ),2007,12(9):989-992.[9] XU H Z. Optimization of antimicrobial dosing regimen according to pharmacolkinetic/pharmacodynamic parameters. Chin Commun Doct(�й�����ҽʦ), 2009,25(3):15-19. [10]SUI Y,GUO T,YAN M, et al. Pharmacokinetics of balofloxacin tablets after a single dose in healthy volunteers. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־),2008,24(1):55-58. [11]XU J F. Population Phamacokinetics and pharmacodynamics of levofloxacin. Shanghai:Fudan University,2009:1-137. [12]CSAJKA C, VEROTTA D. Pharmacokinetic-pharmacodynamic modelling: History and perspectives. J Pharmacokinet Pharmacodyn, 2006, 33(3): 227-279. [13]SUN M J, XU Y. Recent advances and application of pharmacokinetic-pharmacodynamic modeling. Chin J Mod Appl Pharm(�й��ִ�Ӧ��ҩѧ), 2010,27(12):1084-1089. [14]LEE H, YIM D S, ZHOU H, et al. Evidence of effectiveness:How much can we extrapolate from existing studies. AAPS, 2005, 7(2): 467-474. [15]WHITE N J. Pharmacokinetic and parmacodynamic considerations in antimalarial dose optimization. Antimicrobbial Agents and Chemotherapy, 2005,21(8):918-921. [16]MARCHAND S, PARIATC, BOUQUET S, et al. Pharmacokinetic-pharmacodynamicmodelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats.Br J Pharmacol, 2000,129(8) : 1609-1616.
[1] ��տ��, ������*.WHO�Ͳ��ֹ��Ҷ��ƿ���ҩ����ҩ�ԵIJ���[J]. �й�ҩѧ��־, 2014,49(3): 253-256
[2] ��ӱ������ԣ�������罡��*.�ۺϴ�ʩ��Ԥ��Ժ�������ע���ÿ���ҩ����Ӧ�õ�Ч������[J]. �й�ҩѧ��־, 2013,23(9): 751-752
[3] ������*��ʷ¼��*��������.��ԺΧ����Ԥ��ʹ�ÿ���ҩ��Ľ��������[J]. �й�ҩѧ��־, 2013,48(7): 573-576
[4] ��Ӣ,Ҷ��÷.PDCAѭ�����������Χ���ڿ���ҩ��Ԥ��ʹ�õĸ�Ԥ�о�[J]. �й�ҩѧ��־, 2013,48(6): 489-491
[5] �߱�, ������, ������, ������, ����, ����, ������, ������, �����, �����, ½ΰ.����ҩ��ʹ�ü��ָ���һ�����о�[J]. �й�ҩѧ��־, 2013,48(4): 313-316
[6] ��ԣ��ۺ꣬��С�࣬�����.����ҩ��ר�����λ�Կ���ҩ��ʹ��Ӱ�����[J]. �й�ҩѧ��־, 2013,48(23): 2061-2064
[7] �������ܲ���ٿ�������������.�ŵͪ�໯�������ơ��ϳ��뿹���������о�[J]. �й�ҩѧ��־, 2013,48(23): 2055-2060
[8] ������.�ٴ�ҩʦ���ʹ���Χ���ں���ʹ�ÿ���ҩ�������[J]. �й�ҩѧ��־, 2013,48(18): 1596-1597
[9] ����ԥ��������������������־��.DPP-4���Ƽ��ķ��ӽṹ��ҩ��ѧ����[J]. �й�ҩѧ��־, 2013,48(14): 1226-1228
[10] ���Z�أ� ���Һ�*.ͷ����ŵ��ҩԴ�Է���2��[J]. �й�ҩѧ��־, 2013,48(14): 1215-1215
[11] ����������������ΰ��л��ǿ��������������ǿ*.���������ŵͪC-3(��)�ӻ�������2-���ŵͪ-5-����-��NFDE6������������ĺϳ�(��)[J]. �й�ҩѧ��־, 2013,48(14): 1194-1196
[12] ������.102��������ɳ���ٴ�������Ӧ����[J]. �й�ҩѧ��־, 2013,48(10): 830-831
[13] ����ƽ �������� ��Ф������¬����*.��������������ƻ��߿���ҩ����������ٴ�ҩʦ��ԤЧ���Ļع��Է���[J]. �й�ҩѧ��־, 2013,48(10): 827-829
[14] �Ժ�Ӣ.2011����ԺӦ�ÿ���ҩ��Ļع��Է���[J]. �й�ҩѧ��־, 2012,47(8): 646-647
[15] �º�ϼ;�����;ʯ��;��ѩ��;�º�;����ƽ.���ɹ�������Ԥ��ʹ�ÿ���ҩ��Ľ�Ч������[J]. �й�ҩѧ��־, 2012,47(8): 648-649
Copyright 2010 by �й�ҩѧ��־